tetano
Editor, Senior Moderator
J Pediatr
. 2025 Mar 21:114558.
doi: 10.1016/j.jpeds.2025.114558. Online ahead of print. Effectiveness of Influenza Vaccination in Children Aged 6 to 59 Months during the Inaugural 2022-2023 Season in Andalusia, Spain
Almudena Palma-García[SUP] 1 [/SUP], David Moreno-Pérez[SUP] 2 [/SUP], Mario Rivera-Izquierdo[SUP] 3 [/SUP], Manuel Cardero-Rivas[SUP] 4 [/SUP], Jorge Del Diego-Salas[SUP] 2 [/SUP], Nicola Lorusso[SUP] 2 [/SUP]
Affiliations
Objective: To estimate the effectiveness of influenza vaccination when systematic vaccination against influenza was introduced for the first time in Andalusia for the children aged 6 through 59 months, an age group with one of the highest incidence and influenza-related hospitalization rates each season.
Study design: Population-based, retrospective cohort study during the 2022-2923 influenza season of 287,661 children aged 6 to 59 months at the beginning of the inaugural 2022-2023 vaccination campaign. Adjusted vaccine effectiveness (VE) was calculated by estimating multivariable logistic regression models for likelihood of influenza diagnosis in vaccinated and unvaccinated children.
Results: In children aged 6 to 59 months, VE was 51% (95% CI: 48-53%) for preventing infection and 69% (95% CI: 56-79%) for preventing influenza-related hospitalization. In children aged 6 to 23 months, VE was 53% (95% CI: 48-57%) for preventing influenza and 76% (95% CI: 57-87%) for preventing hospitalization due to influenza. In both subpopulations, VE was significantly higher with the two-dose vaccination schedule.
Conclusions: Influenza vaccination shows moderate effectiveness in preventing influenza and high effectiveness in preventing influenza-related hospitalization in children aged 6 to 59 months. This highlights the importance of strengthening influenza vaccination coverage in this age group.
Keywords: Children; Effectiveness; Hospitalization; Influenza; Severity; Vaccination.
. 2025 Mar 21:114558.
doi: 10.1016/j.jpeds.2025.114558. Online ahead of print. Effectiveness of Influenza Vaccination in Children Aged 6 to 59 Months during the Inaugural 2022-2023 Season in Andalusia, Spain
Almudena Palma-García[SUP] 1 [/SUP], David Moreno-Pérez[SUP] 2 [/SUP], Mario Rivera-Izquierdo[SUP] 3 [/SUP], Manuel Cardero-Rivas[SUP] 4 [/SUP], Jorge Del Diego-Salas[SUP] 2 [/SUP], Nicola Lorusso[SUP] 2 [/SUP]
Affiliations
- PMID: 40122278
- DOI: 10.1016/j.jpeds.2025.114558
Objective: To estimate the effectiveness of influenza vaccination when systematic vaccination against influenza was introduced for the first time in Andalusia for the children aged 6 through 59 months, an age group with one of the highest incidence and influenza-related hospitalization rates each season.
Study design: Population-based, retrospective cohort study during the 2022-2923 influenza season of 287,661 children aged 6 to 59 months at the beginning of the inaugural 2022-2023 vaccination campaign. Adjusted vaccine effectiveness (VE) was calculated by estimating multivariable logistic regression models for likelihood of influenza diagnosis in vaccinated and unvaccinated children.
Results: In children aged 6 to 59 months, VE was 51% (95% CI: 48-53%) for preventing infection and 69% (95% CI: 56-79%) for preventing influenza-related hospitalization. In children aged 6 to 23 months, VE was 53% (95% CI: 48-57%) for preventing influenza and 76% (95% CI: 57-87%) for preventing hospitalization due to influenza. In both subpopulations, VE was significantly higher with the two-dose vaccination schedule.
Conclusions: Influenza vaccination shows moderate effectiveness in preventing influenza and high effectiveness in preventing influenza-related hospitalization in children aged 6 to 59 months. This highlights the importance of strengthening influenza vaccination coverage in this age group.
Keywords: Children; Effectiveness; Hospitalization; Influenza; Severity; Vaccination.